Following the successful completion of its deal to acquire GSK’s opiates business in Australia, Sun Pharmaceutical Industries Ltd has begun the process of integration of the acquired business. This deal, first announced in March 2015, fortifies Sun Pharma’s global position with two opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.
Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialised team to drive business growth. Opiates are any of the opioid analgesic alkaloids found as natural products in the opium poppy plant, Papaver somniferum.
The opiates acquisition allows Sun Pharma to significantly expands its narcotics raw material (NRM) market share; enhance opiate alkaloids portfolio & depth in global opiates market; and strengthen its strategic position in the global opiates business.
Anil Kumar Jain, CEO – API business, Sun Pharma, said, “The successful completion of this acquisition enables us to leverage our unique position in the global opiates business by capitalising our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation.”
Source: Business Standard
Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.
Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.
Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.